Management of targeted therapies in hemodialysis patients;Gestion des thérapies ciblées chez les patients hémodialysés

Bulletin du Cancer

Volumn 99, Issue 3, 2012, Pages 381-388

  Janus, Nicolas ^a   Launay Vacher, Vincent ^a   Deray, Gilbert ^a   Islam, Mohamed Shariful ^b   Thyss, Antoine ^c   Thariat, Juliette ^c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b PASTEUR HOSPITAL   (France)

^c CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

Cytotoxic drugs; Dosing recommendations; Hemodialysis; Pharmacokinetics; Targeted therapies

Indexed keywords

MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR;

DRUG EFFICACY; DRUG TOLERABILITY; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FAILURE; MOLECULARLY TARGETED THERAPY; REVIEW;

EID: 84858649731     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2011.1484     Document Type: Article

References (38)

1. Launay-Vacher V, Oudard S, Janus N, et al. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer 2007; 110 : 1376-84. (Pubitemid 47435612)
2. Launay-Vacher V. Epidemiology of chronic kidney disease in cancer patients: lessons from the IRMA study group. Semin Nephrol 2010; 30 : 548-56.
3. Sutherland GA, Glass J, Gabriel R. Increased incidence of malignancy in chronic renal failure. Nephron 1977; 18 : 182-4. (Pubitemid 8085140)
4. Cengiz K. Increased incidence of neoplasia in chronic renal failure (20-year experience). Int Urol Nephrol 2002; 33 : 121-6.
5. Matas AJ, Simmons RL, Kjellstrand CM, Buselmeier TJ, Najarian JS. Increased incidence of malignancy during chronic renal failure. Lancet 1975; 1 : 883-6.
6. Levêque D. Propriétés pharmacocinétiques des anticorps monoclonaux. J Pharm Clin 2002; 21 : 271-7.
7. van Erp NP, Gelderblom H, Guchelaar HJ. Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev 2009; 35 : 692-706.
8. Jillella AP, Dainer PM, Kallab AM, Ustun C. Treatment of a patient with end-stage renal disease with rituximab: pharmacokinetic evaluation suggests rituximab is not eliminated by hemodialysis. Am J Hematol 2002; 71 : 219-22. (Pubitemid 35253340)
9. Feldmann G, Nattermann J, Gerhardt T, Nähle CP, Spengler U, Woitas R. Partial remission of a newly diagnosed diffuse large B-cell non-Hodgkin's lymphoma in a hemodialysis patient after administration of immuno-chemotherapy with rituximab-CHOP. Int J Lab Hematol 2007; 29 : 469-73. (Pubitemid 350060619)
10. Vieira CA, Agarwal A, Book BK, et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation 2004; 77 : 542-8. (Pubitemid 38282809)
11. Lee SY, Hsu PY, Juan KC, Chang H, Huang WH, Lai PC. Successful treatment of autoimmune thrombocytopenic purpura with rituximab in a dialysis patient with systemic lupus erythematosus. Int Immunopharmacol 2010; 10 : 632-4.
12. eed. France : Méditions International, 2008.
13. SiteGPR. Available at: http://www.sitegpr.com/. (Consulté 28 avril 2011).
14. Morita Y, Matsuda M, Yamaguchi T, et al. Efficacy of rituximab monotherapy for an elderly hemodialysis patient with primary cardiac lymphoma. Intern Med 2010; 49 : 2163-6.
15. Baselga J, Pfister D, Cooper MR, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000; 18 : 904-14. (Pubitemid 30106623)
16. Thariat J, Azzopardi N, Peyrade F, et al. Cetuximab pharmacokinetics in end-stage kidney disease under hemodialysis. J Clin Oncol 2008; 26 : 4223-5.
17. Inauen R, Cathomas R, Boehm T, et al. Feasibility of using cetuximab and bevacizumab in a patient with colorectal cancer and terminal renal failure. Oncology 2007; 72 : 209-10. (Pubitemid 351161612)
18. Aldoss IT, Plumb T, Zhen WK, Lydiatt DD, Ganti AK. Cetuximab in hemodialysis: a case report. Head Neck 2009; 31 : 1647-50.
19. Haslbauer F. A case report of successful alemtuzumab treatment of a B-CLL patient suffering from renal failure. Ann Hematol 2009; 88 : 399-400.
20. Garnier-Viougeat N, Rixe O, Paintaud G, et al. Pharmacokinetics of bevacizumab in haemodialysis. Nephrol Dial Transplant 2007; 22 : 975.
21. Micallef RA, Barrett-Lee PJ, Donovan K, Ashraf M, Williams L. Trastuzumab in patients on haemodialysis for renal failure. Clin Oncol (R Coll Radiol) 2007; 19 : 559. (Pubitemid 47181185)
22. Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001; 19 : 3267-79. (Pubitemid 32591445)
23. Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005; 44 : 879-94. (Pubitemid 41252840)
24. Pappas P, Karavasilis V, Briasoulis E, Pavlidis N, Marselos M. Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study. Cancer Chemother Pharmacol 2005; 56 : 358-60. (Pubitemid 41095398)
25. Ozdemir E, Koc Y, Kansu E. Successful treatment of chronic myeloid leukemia with imatinib mesylate in a patient with chronic renal failure on hemodialysis. Am J Hematol 2006; 81 : 474. (Pubitemid 43787945)
26. Nelson MH, Dolder CR. A review of lapatinib ditosylate in the treatment of refractory or advanced breast cancer. Ther Clin Risk Manag 2007; 3 : 665-73. (Pubitemid 47496970)
27. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006; 24 : 25-35. (Pubitemid 46630490)
28. Zastrow S, Froehner M, Platzek I, Novotny V, Wirth MP. Treatment of metastatic renal cell cancer with sunitinib during chronic hemodialysis. Urology 2009; 73 : 868-70.
29. Khosravan R, Toh M, Garrett M, et al. Pharmacokinetics and safety of sunitinib malate in subjects with impaired renal function. J Clin Pharmacol 2010; 50 : 472-81.
30. Josephs D, Hutson TE, Cowey CL, et al. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis. BJU Int 2011; Available at: http://www.ncbi.nlm.nih.gov/ pubmed/21244613. Consulté24 mai 2011.
31. Launay-Vacher V, Izzedine H, Baumelou A, Deray G. FHD: an index to evaluate drug elimination by hemodialysis. Am J Nephrol 2005; 25 : 342-51. (Pubitemid 41160993)
32. Lathia C, Lettieri J, Cihon F, Gallentine M, Radtke M, Sundaresan P. Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol 2006; 57 : 685-92.
33. Miller AA, Murry DJ, Owzar K, et al. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol 2009; 27 : 1800-5.
34. Khan G, Golshayan A, Elson P, et al. Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency. Ann Oncol 2010; 21 : 1618-22.
35. Hilger RA, Richly H, Grubert M, et al. Pharmacokinetics of sorafenib in patients with renal impairment undergoing hemodialysis. Int J Clin Pharmacol Ther 2009; 47 : 61-4.
36. Rey PM, Villavicencio H. Sorafenib: tolerance in patients on chronic hemodialysis: a single-center experience. Oncology 2008; 74 : 245-6.
37. Ruppin S, Protzel C, Klebingat K-J, Hakenberg OW. Successful sorafenib treatment for metastatic renal cell carcinoma in a case with chronic renal failure. Eur Urol 2009; 55 : 986-8, quiz 988.
38. Shinsako K, Mizuno T, Terada T, et al. Tolerable sorafenib therapy for a renal cell carcinoma patient with hemodialysis: a case study. Int J Clin Oncol 2010; 15 : 512-4.